Clinical trial NCT05630872: Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis
Official title: Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: HIV-associated Tuberculosis
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sponsor class: NIH
Collaborators: name: ViiV Healthcare
name: Mylan Inc.
First posted: 2022-11-30
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A5406 hypothesizes that dolutegravir (DTG) 50 mg taken twice daily will provide adequate exposures to maintain viral suppression when dosed with rifapentine (RPT) 1200 mg for HIV-associated TB.

Detailed description: This is an open-label, single arm, phase II, multicenter PK study to investigate the effect of daily RPT 1200 mg on DTG exposure in participants with HIV-associated TB. Adults with HIV with newly diagnosed DS-TB who are not currently on ART will be recruited around the time of DS TB diagnosis. At study entry, the 2HPZM/2HPM regimen will be initiated for anti-tuberculosis (anti-TB) therapy and continued for 17 weeks.

Eligibility criteria: Inclusion Criteria:

1. Individuals ≥18 years of age at study entry.
2. Weight ≥40 kg.
3. Body mass index (BMI) \>18.5 kg/m2.
4. Ability and willingness of participant or legal guardian/representative to provide informed consent.
5. Documentation of HIV-1 status.
6. CD4+ cell count ≥100 cells/mm3 obtained within 30 days prior to study entry at any network-approved non-US laboratory that is IQA certified.
7. ART-naïve or not on ART for 12 consecutive weeks prior to TB diagnosis.
8. Willingness and eligibility to start DTG-based ART at 6 weeks, with a window of ±1 week, after starting TB treatment, with no intention to change ART for the duration of the study.
9. Documentation of pulmonary TB.
10. Willingness to start 2HPZM/2HPM therapy for DS-TB.
11. The following laboratory values obtained within 30 days prior to study entry:

    * Absolute neutrophil count (ANC) \>750 cells/mm3
    * Hemoglobin ≥7.4 g/dL
    * Platelet count ≥50,000/mm3
    * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) \<2.5 X the upper limit of normal (ULN)
    * Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) \<2.5 x ULN
    * Total bilirubin ≤1.5 x ULN
    * Creatinine \<1.3 x ULN
12. For participants who can become pregnant, negative serum or urine pregnancy test at screening within 30 days prior to entry and within 48 hours prior to entry.
13. Participants who can become pregnant must agree not to participate in the conception process and if participating in sexual activity that could lead to pregnancy, must agree to use one reliable nonhormonal method of contraception.
14. Documentation of Karnofsky performance score ≥50 within 30 days prior to entry.

Exclusion Criteria:

1. Breastfeeding, pregnant, or plans to become pregnant.
2. Known allergy/sensitivity or any hypersensitivity to components of the study drugs, or their formulations.
3. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
4. Requirement for ongoing use of drugs that are known to have significant drug-drug interactions with DTG or RPT.
5. Known history of acute intermittent porphyria.
6. Previous treatment for active TB disease.
7. More than 5 days of treatment directed against active TB for the current TB episode preceding study entry.
8. At the time of study entry, documentation of an M. tuberculosis isolate from the current or previous treatment episode known to be resistant to RIF or INH.
9. Known history of prolonged QT syndrome.
10. Known cirrhosis, a history of decompensated liver disease (ascites, hepatic encephalopathy, or esophageal varices).
11. Documentation of severe opportunistic infections, in the opinion of the site investigator, within 3 months of study entry.
12. Documentation of severe extra-pulmonary TB (e.g., meningitis, osteomyelitis, disseminated TB) at the time of screening.
13. Acute gout at the time of screening.

Primary outcomes:
measure: Model-simulated 5th percentile and corresponding 95% confidence interval of DTG minimum concentrations (Cmin) at 50 mg BID when co-administered with daily RPT 1200 mg plus HZM
timeFrame: 48 Weeks
Secondary outcomes:
measure: DTG minimum concentration (Cmin)
timeFrame: 48 Weeks
measure: DTG minimum concentration (Cmax)
timeFrame: 48 Weeks
measure: DTG area under the concentration-time curve (AUC0-24)
timeFrame: 48 Weeks
measure: Number of participants who experience Grade 3 or higher AEs
timeFrame: Weeks 6-17
measure: Number of participants who have a diagnosis of rifamycin hypersensitivity
timeFrame: Weeks 6-17
measure: Number of participants who experience ALT ≥3xULN with symptoms/jaundice or ALT ≥5xULN
timeFrame: Weeks 6-17
measure: Number of participants who prematurely discontinue study drugs DTG and/or RPT
timeFrame: Weeks 6-17
measure: Proportion of participants with HIV-1 viral load below 50 copies/mL
timeFrame: Weeks 10, 14, 21, and 30
Other outcomes:
Locations:
city: Mowbray
country: South Africa
facility: University of Cape Town Lung Institute (UCTLI) CRS (Site # 31792)
state: Cape Town, Western Cape
city: Westridge
country: South Africa
facility: Durban International CRS (Site # 11201)
state: Durban RSA
city: Worcester
country: South Africa
facility: South African Tuberculosis Vaccine Initiative (SATVI) CRS (Site # 31793)
state: Western Province
city: Bangkok
country: Thailand
facility: Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site # 31802)
Study officials:
References: